Pharmacology
Ziprasidone has the high affinity for dopamine, serotonin, and alpha-adrenergic receptors and the medium affinity for histaminic receptors. Ziprasidone is somewhat unique among a "atypicals" therein it as well displays a bit of inhibition of synaptic re-uptake of serotonin and norepinephrine, although the clinical significance of this is unknown. A mechanism of action of ziprasidone is unknown. But these are theorized that its antipsychotic activity is mediated primarily by antagonism at dopamine receptors, specifically D2. Five-hydroxytryptamine antagonism might too play a role in the effectiveness of ziprasidone, however the significance of 5-HT2A antagonism is debated among investigator. Antagonism at histaminic & alpha sympathomimetic receptors belike explains a select few of the side results of ziprasidone, like sedation and orthostasis.

Pharmacokinetics
A systemic bioavailability of ziprasidone administered intramuscularly is 100%, or even 60%, administered orally sustaining food. Fallowing one dose intramuscular administration, a peak blood serum concentration occasionally occurs at astir Hour when a dose is administered, or even earliest. Steadily state plasma concentrations come achieved in of these to 3 years. A mean half-life (T 1/2) ranges from either two to 5 hours. Exposure increases within the dose-related manner & as punishment terzetto years of intramuscular dosing, little accumulation is found.

Metabolism
Ziprasidone is hepatically metabolized by aldehyde reductase. Minor metabolism occurs via cytochrome P450 3A4. Medication that cause (e.g carbamazepine) or inhibit (e.g. ketoconazole) CYP3A4 have been shown to decrease & increase, severally, blood levels of ziprasidone. No known causes or even inhibitors of aldehyde reductase.

Adverse Events
Ziprasidone will increase a QTc interval in some patients and might increase the chance of a nature and severity of heart arrythmia called torsades de pointes. Ziprasidone should become utilized cautiously around patients ingesting more medications in all likelihood to interact by owning ziprasidone or even increase a QTc interval.

Adverse cases reported for ziprasidone include sedation, insomnia, orthostasis, akathisia and other lasting extrapyramidal side-effects such as tardive dyskinesia.

Recently, a FDA called upon a manufacturers of completely untypical antipsychotics to include a warning just about the chance of hyperglycemia and Type II diabetes with atypical antipsychotics. A select few grounds to believe suggests that ziprasidone might not become when badness when a few of the more untypical antipsychotics at stimulating insulin resistance and weight gain. inside point of fact, in the test of yearn term therapy using ziprasidone, heavy patients (BMI>27) actually had the mean weight loss overall. Ziprasidone, though, is non the weight loss drug. A weight loss reflected therein learn in ziprsidone was really reflective of patients world health organizatiin experienced gained weight on more antipsychotics world health organization were okay, trending back toward their baseline.